A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects
- PMID: 38852522
- DOI: 10.1016/j.intimp.2024.112393
A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects
Abstract
Recombinant adenovirus serotype 5 (Ad5)-mediated virotherapy is a maturing technique in cancer treatment. However, the utility of adenovirus (Ad) has been limited by low expression of coxsackievirus and adenovirus receptor (CAR) in cancer cells resulting in poor infectivity of Ads. To overcome the problem, we aimed to develop a novel tropism-modified oncolytic adenovirus, ZD55-F-HI-sPD-1-EGFP, which contains the epitope of PD-1 (70-77aa) at the HI-loop of Ad fiber. Trimerization of Fiber-sPD-1 was confirmed by immunoblot analysis. ZD55-F-HI-sPD-1-EGFP shows a remarkable improvement in viral infection rate and gene transduction efficiency in the PD-L1-positive cancer cells. Competition assays with a PD-L1 protein reveals that cell internalization of ZD55-F-HI-sPD-1-EGFP is mediated by both CAR and PD-L1 at a high dose. The progeny virus production capacity showed that sPD-1 incorporated fiber-modified oncolytic Ad replication was not affected. Furthermore, treating with ZD55-F-HI-sPD-1-EGFP significantly increased viral infection rate and enhanced anti-tumor effect in vivo. This study demonstrates that the strategy to expand tropism of oncolytic Ad may significantly improve therapeutic profile for cancer treatment.
Keywords: Oncolytic adenovirus; PD-L1 tropism-expanded; Viral infectivity; sPD-1.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth.Oncotarget. 2015 Oct 27;6(33):34875-91. doi: 10.18632/oncotarget.5332. Oncotarget. 2015. PMID: 26430798 Free PMC article.
-
Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.Hum Gene Ther. 2012 Sep;23(9):960-79. doi: 10.1089/hum.2011.218. Epub 2012 Aug 27. Hum Gene Ther. 2012. PMID: 22708837 Clinical Trial.
-
Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.Cancer Sci. 2013 Nov;104(11):1433-9. doi: 10.1111/cas.12267. Epub 2013 Sep 23. Cancer Sci. 2013. PMID: 23962292 Free PMC article.
-
Recent advances in oncolytic adenovirus therapies for cancer.Curr Opin Virol. 2016 Dec;21:9-15. doi: 10.1016/j.coviro.2016.06.009. Epub 2016 Jul 2. Curr Opin Virol. 2016. PMID: 27379906 Free PMC article. Review.
-
Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIX.Virus Res. 2018 Sep 15;257:40-51. doi: 10.1016/j.virusres.2018.08.012. Epub 2018 Aug 17. Virus Res. 2018. PMID: 30125593 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials